Tenderwize
Back to tender search

Non-exclusive Drug Discount Agreement for Aripiprazole (Parenteral)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Mar 31, 2027 · 174 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aripiprazol für die parenterale Applikation (ATC-Code nach WHO: N05AX12)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

No guaranteed volume; actual sales depend on prescription and pharmacy behavior, leading to unpredictable revenue.

Early termination risk: buyer may cancel the Open House if exclusive agreements are made (typically 8-12 months after p...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Mar 31, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Conclusion of non-exclusive discount agreements for Aripiprazole parenteral products
  • Supply of pharmaceutical products to AOK PLUS for patients in Saxony and Thuringia
Show full summary

This Open House model tender by AOK PLUS seeks non-exclusive discount agreements under §130a Abs. 8 SGB V for the active substance Aripiprazole for parenteral administration (ATC N05AX12). The framework agreement is open to all eligible pharmaceutical companies meeting participation requirements. No exclusivity, no minimum purchase quantities, and no estimated value are provided. The contract runs until 31 March 2027. Submissions are accepted periodically, with the first deadline on 5 March 2025. The procedure is not subject to public procurement law; the notice is published for transparency. All communication and document access are via the DTVP portal, with strict confidentiality required.

Risks

No guaranteed volume; actual sales depend on prescription and pharmacy behavior, leading to unpredictable revenue.

Early termination risk: buyer may cancel the Open House if exclusive agreements are made (typically 8-12 months after p...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company as defined by §4 Abs. 18 AMG for the offered products

Eligibility

  • Submit self-declaration on exclusion grounds (GWB §§123,124)

Administrative

  • Submit self-declaration regarding EU Russia sanctions (Art. 5k of Regulation 833/2014)

Requirements may be incomplete.

Award Criteria

Lot 1

No explicit award criteria specified in the notice. Participation is open to all fulfilling conditions.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Aripiprazole (Parenteral)

Framework agreement for non-exclusive discount agreements on Aripiprazole parenteral formulations. Open House model; no exclusivity, no guaranteed volumes. Contract ends 31 March 2027.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Mar 2025 - Mar 2027

Category

Pharmaceutical products

Award Criteria

No explicit award criteria specified in the notice. Participation is open to all fulfilling conditions.

Deadline

Deadline Mar 31, 2027

Procurement Details

Publication date
22 Jan 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
48010-2025

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30